India's Cadabams invests $7.3m in AI mental health platform MindTalk

Cadabams Group, a mental healthcare provider based in India, has announced a US$7.3 million investment in its digital mental health platform MindTalk.

Only a part of the funds has been invested so far, with the rest to be deployed over the next 12 to 18 months to build MindTalk’s AI infrastructure and support clinical research integration.

MindTalk uses large language models, conversational AI, and adaptive learning, all supervised by clinicians, to deliver evidence-based mental health guidance.

Cadabams operates 42 centers across India and the Maldives, and plans to expand both its physical and digital services.

The company aims for MindTalk to reach 1 million users as demand for mental health support grows in India.

🔗 Source: YourStory

🧠 Food for thought

Implications, context, and why it matters.

MindTalk’s clinical standing needs SaMD clarity

MindTalk draws on Cadabams’ over three decades of clinical practice and uses clinician-supervised AI 1. The funding news does not say if it holds Software as a Medical Device (SaMD) status under India’s Medical Device Rules (MDR) 2017, which set risk classes and licensing, or if it aligns with CDSCO’s October 2025 draft guidance for medical-purpose software 2 3.
The draft sets Quality Management System (QMS) expectations and use of the MD Online Portal, CDSCO’s device licensing system, for medical software 2. The article gives no regulatory path or clinical validation, meaning studies on safety and effectiveness 3.
Without clear SaMD classification or licensing, buyers may see MindTalk as a wellness tool rather than a clinical-grade product. This can limit insurer reimbursement and hospital adoption 3. Cadabams runs 42 centres in India and the Maldives. It reports care for over 275,000 patients 3.

Third-party SaMD firms can benefit from changing rules in India

AI mental health apps are growing in India, so specialist firms can offer SaMD regulatory help. They can guide risk class selection under CDSCO’s system, Class A through D, and file via the MD Online Portal 2.
CDSCO now says a separate loan license, which permits manufacture using another entity’s facilities, need not be insisted upon for outsourced sterilization under set conditions 4. That process is third-party work usually tied to hardware devices. The change updates oversight, creating demand for QMS documents and audits for software-based medical devices.